查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1446526

重組蛋白治療 CDMO 市場規模、佔有率、趨勢分析報告：按類型、來源、適應症、地區、細分市場預測，2024-2030 年

Recombinant Protein Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents, Others), By Source, By Indication, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 173 Pages | 商品交期: 2-10個工作天內

價格

重組蛋白治療 CDMO 市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球重組蛋白治療CDMO市場將達到520億美元，2024年至2030年複合年成長率為13.95%。

新型重組蛋白療法開發方面不斷湧現的技術創新以及生技藥品研發的不斷增加預計將對重組蛋白治療 CDMO 產業產生積極影響。由於各種技術創新，新型重組蛋白療法的開發取得了重大進展。

重組蛋白是將編碼所需蛋白的基因引入宿主細胞（通常是微生物或哺乳動物細胞）以表達和生產所需蛋白而產生的生物技術蛋白。目前正在採用多種蛋白質工程平台技術來瞄準精度和功能，並提高新型蛋白質療法的循環半衰期。這些技術還旨在提高產量並確保產品純度。

此外，隨著越來越多的公司投資於含有重組蛋白的生技藥品的研發，生物製藥產業正在經歷顯著成長。這種成長是由製造技術的進步所推動的，包括採用一次性反應器和其他創新製造方法。例如，2024 年 1 月，Eurofins CDMO Alphora, Inc. 宣布完成了一個中試規模的生技藥品開發設施。該設施佔地 3,300 平方英尺，致力於單株抗體 (mAb) 和其他哺乳動物來源的治療性蛋白質的開發和規模化生產。

此外，全球自體免疫、自體免疫疾病和代謝性疾病等慢性和複雜疾病的盛行率不斷上升，增加了對創新和有效治療方案的需求。重組蛋白療法提供了多種候選藥物來解決這些複雜的疾病狀態。例如，美國癌症協會估計，2023 年美國將新增約 1,958,310 例癌症病例，並有 609,820 例癌症相關死亡。此外，根據牛津大學發表的研究論文，到2022年6月核准並上市的抗體療法數量將達到162種，其中約一半（42.6%）是為癌症治療而開發的。

2023年3月，美國FDA加速核准Incyte公司的retifanlimab-dlwr用於治療轉移性或復發性局部晚期默克爾細胞癌（MCC）成年患者。癌症的生物療法也支持修復、刺激和增強免疫反應。因此，許多製藥和生物製藥公司都渴望投資新的癌症相關治療方法。總的來說，這些進步旨在生產越來越多的高品質產品。

重組蛋白治療 CDMO 市場報告亮點

  • 2023年，其他細分市場將主導市場。該領域的成長是由重組蛋白療法的興起所推動的，重組蛋白療法是比血漿衍生產品更安全的選擇，因為它們具有減少感染疾病源性傳播的潛力。
  • 從供應來源來看，哺乳動物系統佔最大市場佔有率，2023年將達67.4%。這是由於擴大採用哺乳動物系統作為重組蛋白的來源。哺乳動物細胞培養系統有利於生產具有適當轉譯後修飾的複雜蛋白質，使其適用於廣泛的治療應用。
  • 有跡象表明，到2023年，代謝疾病細分市場將佔21.8%的市場佔有率。該行業受到人口老化和製藥行業強勁需求的推動，從而促進了該行業的崛起。
  • 2023 年，北美市場佔據主導地位，佔有率為 38.5%。該地區擁有強大的研發基礎設施和強勁的生物製藥產業，有助於市場成長。此外，美國擁有高度發展的生物製藥生產基礎設施，包括重組蛋白療法。

目錄

第1章調查方法與範圍

第 2 章 第 2 章執行摘要

  • 市場概述
  • 分段簡介
  • 競爭形勢概覽

第 3 章 重組蛋白治療 CDMO 市場：變數、趨勢、範圍

  • 市場體系展望
  • 重組蛋白治療 CDMO 市場動態
  • 重組蛋白治療 CDMO 市場：分析工具
  • COVID-19 對重組蛋白治療 CDMO 市場的影響
  • COVID-19 對生物加工和外包的影響

第 4 章 重組蛋白治療 CDMO 市場：類型估計與趨勢分析

  • 定義和範圍
  • 細分儀表板
  • 全球重組蛋白治療CDMO市場波動分析
  • 2018-2030 年全球重組蛋白治療 CDMO 市場規模及趨勢分析（按類型）

第5章重組蛋白治療 CDMO 市場：來源估計與趨勢分析

  • 定義和範圍
  • 細分儀表板
  • 全球重組蛋白治療CDMO市場波動分析
  • 2018-2030 年全球重組蛋白治療 CDMO 市場規模及趨勢分析（依來源）

第6章重組蛋白治療CDMO市場：適應症估計與趨勢分析

  • 定義和範圍
  • 細分儀表板
  • 全球重組蛋白治療CDMO市場波動分析
  • 2018-2030年全球重組蛋白治療CDMO市場規模及趨勢分析（依適應症）

第 7 章 重組蛋白治療 CDMO 市場：按類型、來源和適應症分類的區域估計和趨勢分析

  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030年市場規模及預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭形勢

  • 公司分類
  • 2023 年重組蛋白治療 CDMO市場佔有率分析
  • Major Deals and Strategic Alliances Analysis
    • 策略規劃
    • 擴張
    • 合夥
    • 獲得
  • 供應商形勢
    • Key company market share analysis, 2023
    • Richter-Helm BioLogics
    • Lonza
    • Catalent, Inc
    • FUJIFILM Diosynth Biotechnologies
    • WuXi Biologics
    • Curia Global, Inc.
    • Batavia Biosciences BV
    • HALIX BV
    • BIOVIAN
    • Enzene Biosciences Ltd
Product Code: GVR-4-68040-116-2

Recombinant Protein Therapeutics CDMO Market Growth & Trends:

The global recombinant protein therapeutics CDMO market is expected to reach USD 52.0 billion by 2030 and is expected to expand at a CAGR of 13.95% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing technological innovations about the development of novel recombinant protein therapeutics and rising research and development for biologics are anticipated to influence the recombinant protein therapeutics CDMO industry positively. The development of novel recombinant protein therapeutics has observed significant advancements due to various technological innovations.

Recombinant proteins are bioengineered proteins produced by introducing the gene encoding the desired protein into a host cell, typically a microorganism or a mammalian cell, to express and produce the protein of interest. Several protein engineering platform technologies are currently employed to enhance the circulating half-life, targeting the precision and functionality of novel therapeutic protein drugs. These technologies also aim to boost production yield and ensure product purity.

Besides, the biopharmaceutical industry has witnessed significant growth, with an increasing number of companies investing in research and development of biologics, including recombinant proteins. This growth has been facilitated by advancements in manufacturing technologies, including adopting single-use bioreactors and other innovative production methods. For instance, in January 2024, Eurofins CDMO Alphora, Inc. announced the successful completion of its pilot-scale biologics development facility. With an expansive area of 3,300 square feet, this facility is exclusively dedicated to developing and scaling monoclonal antibodies (mAbs) and other therapeutic proteins derived from mammalian sources.

Moreover, the global increase in the prevalence of chronic and complex diseases, such as cancer, autoimmune disorders, & metabolic diseases, has increased the demand for innovative and effective therapeutic options. Recombinant protein therapeutics offer a diverse range of candidates to address these complex medical conditions. For instance, based on estimates from the American Cancer Society, it is projected that in 2023, there will be approximately 1,958,310 new cases of cancer and 609,820 cancer-related deaths in the U.S. Furthermore, according to a research article published by Oxford University, in June 2022, the number of approved and marketed antibody therapies reached 162, nearly half of which (42.6%) were being developed for the treatment of cancer.

In March 2023, the U.S. FDA granted accelerated clearance to Incyte Corporation's retifanlimab-dlwr for the treatment of adult patients with metastatic or recurrent, locally advanced Merkel Cell Carcinoma (MCC). Besides, biological therapy in cancer supports repairing, stimulating, or enhancing the immune response. Therefore, many pharmaceutical & biopharmaceutical companies are willing to invest in cancer-related novel treatments.Such advancements collectively aim to achieve a higher yield of quality products.

Recombinant Protein Therapeutics CDMO Market Report Highlights:

  • The others segment dominated the market in 2023. The segment growth is driven by increasing recombinant protein therapies as a safer option than plasma-derived products owing to the potential to reduce bloodborne transmission of infectious diseases
  • Based on the source, mammalian systems held the largest market share of 67.4% in 2023 attributed to an increase in the adoption of mammalian systems for sourcing recombinant proteins. Mammalian cell culture systems offer advantages in producing complex proteins with appropriate post-translational modifications, making them suitable for a wide range of therapeutic applications
  • Based on indication, the metabolic disorders segment held a market share of 21.8% in 2023. The segment is driven by a growing aging population, and robust demand for pharmaceutical industry, which has contributed to its prominence in this field
  • North America dominated the market with a share of 38.5% in 2023. The region has a strong R&D infrastructure and a robust biopharmaceutical industry, which has contributed to the market growth. Furthermore, the U.S. has a sophisticated and well-developed manufacturing infrastructure for biopharmaceuticals, including recombinant protein therapeutics

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's InternalL Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
    • 1.3.5. Details Of Primary Research
  • 1.4. Information Or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. Market Definitions
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objective - 1
    • 1.10.2. Objective - 2
    • 1.10.3. Objective - 3
    • 1.10.4. Objective - 4

Chapter 2. Chapter 2 Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Recombinant Protein Therapeutics CDMO Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Recombinant Protein Therapeutics CDMO Market Dynamics
    • 3.2.1. Market Driver Impact Analysis
      • 3.2.1.1. Rising Adoption Of Biologics And Biosimilars
      • 3.2.1.2. Technological Innovations About The Development Of Novel Recombinant Protein Therapeutics
      • 3.2.1.3. Increasing Rate Of Clinical Research To Boost Demand For Recombinant Protein Therapeutics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory Hurdles
      • 3.2.2.2. Challenges Related To Quality Control
  • 3.3. Recombinant Protein Therapeutics CDMO Market: Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
  • 3.4. Impact Of Covid-19 On Recombinant Protein Therapeutics CDMO Market
  • 3.5. Covid-19 Impact On Bioprocessing And Outsourcing
    • 3.5.1. Clinical Trial Supply & Logistics Services: Impact Of Covid-19
    • 3.5.2. Supply Chain
    • 3.5.3. Activities By CDMOs Increased Post-Covid-19 Pandemic, Supporting The Development Of Recombinant Protein Therapeutics
    • 3.5.4. Changes In The Long Term

Chapter 4. Recombinant Protein Therapeutics CDMO Market: Type Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Growth Hormones
    • 4.1.2. Interferons
    • 4.1.3. Vaccines
    • 4.1.4. Immunostimulating Agents
    • 4.1.5. Others
  • 4.2. Segment Dashboard
  • 4.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
  • 4.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
    • 4.4.1. Growth Hormones
      • 4.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.2. Interferons
      • 4.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.3. Vaccines
      • 4.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.4. Immunostimulating Agents
      • 4.4.4.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 5. Recombinant Protein Therapeutics CDMO Market: Source Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Mammalian Systems
    • 5.1.2. Microbial Systems
    • 5.1.3. Others
  • 5.2. Segment Dashboard
  • 5.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
  • 5.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Source, 2018 to 2030 (USD Million)
    • 5.4.1. Mammalian Systems
      • 5.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 5.4.2. Microbial Systems
      • 5.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 5.4.3. Others
      • 5.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 6. Recombinant Protein Therapeutics CDMO Market: Indication Estimates & Trend Analysis

  • 6.1. Definitions and Scope
    • 6.1.1. Oncology
    • 6.1.2. Infectious Diseases
    • 6.1.3. Immunological Disorders
    • 6.1.4. Metabolic Disorders
    • 6.1.5. Haematological Disorders
    • 6.1.6. Others
  • 6.2. Segment Dashboard
  • 6.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
  • 6.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
    • 6.4.1. Oncology
      • 6.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.2. Infectious Diseases
      • 6.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.3. Immunological Disorders
      • 6.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.4. Metabolic Disorders
      • 6.4.4.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.5. Haematological Disorders
      • 6.4.5.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 7. Recombinant Protein Therapeutics CDMO Market: Regional Estimates & Trend Analysis by Type, Source, Indication

  • 7.1. Regional Market Dashboard
  • 7.2. Global Regional Market Snapshot
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Scenario
      • 7.4.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Scenario
      • 7.4.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Scenario
      • 7.5.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Scenario
      • 7.5.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Scenario
      • 7.5.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Scenario
      • 7.5.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Scenario
      • 7.5.6.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Scenario
      • 7.5.7.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Scenario
      • 7.5.8.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Scenario
      • 7.5.9.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Scenario
      • 7.6.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Scenario
      • 7.6.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Scenario
      • 7.6.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Scenario
      • 7.6.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Scenario
      • 7.6.6.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.7. South Korea
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Scenario
      • 7.6.7.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Scenario
      • 7.7.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.7.3. Mexico
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Scenario
      • 7.7.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.7.4. Argentina
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Scenario
      • 7.7.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Scenario
      • 7.8.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Scenario
      • 7.8.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Scenario
      • 7.8.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Scenario
      • 7.8.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Recombinant Protein Therapeutics CDMO Market Share Analysis, 2023
  • 8.3. Major Deals and Strategic Alliances Analysis
    • 8.3.1. Strategy Mapping
    • 8.3.2. Expansion
    • 8.3.3. Partnerships
    • 8.3.4. Acquisitions
  • 8.4. Vendor Landscape
    • 8.4.1. Key company market share analysis, 2023
    • 8.4.2. Richter-Helm BioLogics
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Lonza
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Catalent, Inc
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. FUJIFILM Diosynth Biotechnologies
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. WuXi Biologics
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Curia Global, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Batavia Biosciences B.V.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. HALIX B.V.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. BIOVIAN
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Enzene Biosciences Ltd
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 5 North America Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 6 U.S. Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 8 U.S. Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 9 Canada Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 11 Canada Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Europe Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 14 Europe Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 15 Europe Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 16 UK Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 17 UK Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 18 UK Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 19 Germany Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 20 Germany Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 21 Germany Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 22 France Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 23 France Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 24 France Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Italy Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 26 Italy Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 27 Italy Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Spain Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 29 Spain Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 30 Spain Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 31 Denmark Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 32 Denmark Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 33 Denmark Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 34 Sweden Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 35 Sweden Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 36 Sweden Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 37 Norway Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 38 Norway Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 39 Norway Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Japan Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 45 Japan Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 46 Japan Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 47 China Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 48 China Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 49 China Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 50 India Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 51 India Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 52 India Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 53 Australia Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 54 Australia Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 55 Australia Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 56 Thailand Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 57 Thailand Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 58 Thailand Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 59 South Korea Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 61 South Korea Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Latin America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 64 Latin America Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 65 Brazil Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 66 Brazil Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 67 Brazil Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 68 Mexico Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 69 Mexico Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 70 Mexico Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 71 Argentina Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 72 Argentina Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 73 Argentina Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 74 MEA Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 76 MEA Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 77 MEA Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 78 South Africa Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 79 South Africa Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 80 South Africa Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 84 UAE Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 85 UAE Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 86 UAE Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 87 Kuwait Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Recombinant protein therapeutics CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD model sizing & forecasting
  • Fig. 10 Bottom-up approach
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market outlook, 2022 (USD Billion)
  • Fig. 16 Ancillary market outlook, 2022 (USD Billion)
  • Fig. 17 Recombinant protein therapeutics CDMO market dynamics
  • Fig. 18 Porter's five forces analysis
  • Fig. 19 PESTEL analysis
  • Fig. 20 Recombinant protein therapeutics CDMO market type outlook: Segment dashboard
  • Fig. 21 Recombinant protein therapeutics CDMO market, by type segment: Market share, 2023 & 2030
  • Fig. 22 Growth hormones market, 2018 - 2030 (USD Million)
  • Fig. 23 Interferons market, 2018 - 2030 (USD Million)
  • Fig. 24 Vaccines market, 2018 - 2030 (USD Million)
  • Fig. 25 Immunostimulating agents market, 2018 - 2030 (USD Million)
  • Fig. 26 Others market, 2018 - 2030 (USD Million)
  • Fig. 27 Recombinant protein therapeutics CDMO market source outlook: Segment dashboard
  • Fig. 28 Recombinant protein therapeutics CDMO market, by source segment: Market share, 2023 & 2030
  • Fig. 29 Mammalian systems market, 2018 - 2030 (USD Million)
  • Fig. 30 Microbial systems market, 2018 - 2030 (USD Million)
  • Fig. 31 Others market, 2018 - 2030 (USD Million)
  • Fig. 32 Recombinant protein therapeutics CDMO market indication outlook: Segment dashboard
  • Fig. 33 Recombinant protein therapeutics CDMO market, by indication segment: Market share, 2023 & 2030
  • Fig. 34 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 35 Infectious diseases market, 2018 - 2030 (USD Million)
  • Fig. 36 Immunological disorders market, 2018 - 2030 (USD Million)
  • Fig. 37 Metabolic disorders market, 2018 - 2030 (USD Million)
  • Fig. 38 Haematological disorders market, 2018 - 2030 (USD Million)
  • Fig. 39 Others market, 2018 - 2030 (USD Million)
  • Fig. 40 Regional market: Key takeaways
  • Fig. 41 Regional marketplace: Key takeaways
  • Fig. 42 Regional marketplace: Key takeaways
  • Fig. 43 North America recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 U.S. recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Canada recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 48 Europe recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 UK recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Germany recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 France recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Italy recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Spain recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Denmark recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Norway recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Japan recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 China recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 India recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Australia recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Clinical trial approval process in South Korea
  • Fig. 76 South Korea recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Thailand recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 79 Latin America recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Brazil recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Mexico recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Argentina recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 86 MEA recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 South Africa recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Saudi Arabia recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 Clinical trial authorization process UAE
  • Fig. 93 UAE recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Kuwait recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 96 Market participant categorization
  • Fig. 97 Market participant categorization
  • Fig. 98 Heat map analysis